CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

doi:10.1038/s41408-017-0023-x

. 2017 Dec 20;7(12):659.

doi: 10.1038/s41408-017-0023-x.

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

E Mejstríková¹, O Hrusak¹, M J Borowitz², J A Whitlock³, B Brethon⁴, T M Trippett⁵, G Zugmaier⁶, L Gore⁷, A von Stackelberg⁸, F Locatelli^{9

10}

Affiliations

¹ Department of Pediatric Hematology/Oncology, CLIP, Charles University, Prague, Czech Republic.
² Hematologic Pathology, Johns Hopkins University, Baltimore, MD, USA.
³ University of Toronto, Hospital for Sick Children, Toronto, ON, Canada.
⁴ Department of Pediatric Hematology, Robert Debre Hospital, Paris, France.
⁵ Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Global Development, Amgen Research (Munich) GmbH, Munich, Germany. gerhardz@amgen.com.
⁷ University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
⁸ Charité University Medical Center, Berlin, Germany.
⁹ Department of Pediatric Hematology-Oncology, IRCCS Ospedale Bambino Gesù, Rome, Italy.
¹⁰ University of Pavia, Pavia, Italy.

PMID: 29259173
PMCID: PMC5802535
DOI: 10.1038/s41408-017-0023-x

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

E Mejstríková et al. Blood Cancer J. 2017.

. 2017 Dec 20;7(12):659.

doi: 10.1038/s41408-017-0023-x.

Authors

E Mejstríková¹, O Hrusak¹, M J Borowitz², J A Whitlock³, B Brethon⁴, T M Trippett⁵, G Zugmaier⁶, L Gore⁷, A von Stackelberg⁸, F Locatelli^{9

10}

Affiliations

¹ Department of Pediatric Hematology/Oncology, CLIP, Charles University, Prague, Czech Republic.
² Hematologic Pathology, Johns Hopkins University, Baltimore, MD, USA.
³ University of Toronto, Hospital for Sick Children, Toronto, ON, Canada.
⁴ Department of Pediatric Hematology, Robert Debre Hospital, Paris, France.
⁵ Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Global Development, Amgen Research (Munich) GmbH, Munich, Germany. gerhardz@amgen.com.
⁷ University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
⁸ Charité University Medical Center, Berlin, Germany.
⁹ Department of Pediatric Hematology-Oncology, IRCCS Ospedale Bambino Gesù, Rome, Italy.
¹⁰ University of Pavia, Pavia, Italy.

PMID: 29259173
PMCID: PMC5802535
DOI: 10.1038/s41408-017-0023-x

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests

E.M., O.H., and M.J.B. performed MRD assessments as a service to Amgen. M.J.B. reports research grants from Becton Dickinson Biosciences and participated on a speakers bureau for Beckman Coulter. J.A.W. reports research grants/funding for trials from Novartis and Amgen and consulting fees from Jazz Pharmaceuticals, Shire, Amgen, and Gilead. G.Z. is an employee of and owns stock in Amgen. L.G. received consulting fees from Amgen, Novartis, and Celgene; is on the board of directors for Round River Ranch/Serious Fun Network; and owns stock in Amgen, Celgene, Clovis Oncology, and Sanofi PARIS. A.V.S. reports consulting fees from Amgen. The remaining authors (B.B., T.M.T., and F.L.) declare that they have no competing financial interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

**Fig. 1**
**Flow cytometric profiles of blasts from four patients with CD19-negative relapse after blinatumomab treatment and one control patient during treatment.** a Patient #1, b Patient #2, c Patient #3, d Patient #4, and e control patient

See this image and copyright information in PMC

Cited by

Blinatumomab Prior to CAR-T Cell Therapy-A Treatment Option Worth Consideration for High Disease Burden.
Marschollek P, Liszka K, Mielcarek-Siedziuk M, Rybka B, Ryczan-Krawczyk R, Panasiuk A, Olejnik I, Frączkiewicz J, Dachowska-Kałwak I, Mizia-Malarz A, Szczepański T, Młynarski W, Styczyński J, Drabko K, Karolczyk G, Gorczyńska E, Maciej Zaucha J, Kałwak K. Marschollek P, et al. Biomedicines. 2022 Nov 13;10(11):2915. doi: 10.3390/biomedicines10112915. Biomedicines. 2022. PMID: 36428483 Free PMC article.
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Lamble AJ, et al. Blood Adv. 2023 Feb 28;7(4):575-585. doi: 10.1182/bloodadvances.2022007423. Blood Adv. 2023. PMID: 35482927 Free PMC article.
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Kansagra AJ, et al. Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18. Biol Blood Marrow Transplant. 2019. PMID: 30576834 Free PMC article.
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN. Myers RM, et al. J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12. J Clin Oncol. 2022. PMID: 34767461 Free PMC article.
Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A, Mikhailova E, Komkov A, Gaskova M, Abasov R, Matveev E, Kazanov M, Mamedov I, Shmitko A, Belova V, Miroshnichenkova A, Illarionova O, Olshanskaya Y, Tsaur G, Verzhbitskaya T, Ponomareva N, Bronin G, Kondratchik K, Fechina L, Diakonova Y, Vavilova L, Myakova N, Novichkova G, Maschan A, Maschan M, Zerkalenkova E, Popov A. Semchenkova A, et al. Int J Mol Sci. 2022 Apr 5;23(7):4019. doi: 10.3390/ijms23074019. Int J Mol Sci. 2022. PMID: 35409391 Free PMC article.

See all "Cited by" articles

References

1. Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 2016;14:357–362. doi: 10.1016/j.csbj.2016.09.003. - DOI - PMC - PubMed
1. Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer. 2016;63:1113–1115. doi: 10.1002/pbc.25953. - DOI - PubMed
1. Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295. doi: 10.1158/2159-8290.CD-15-1020. - DOI - PMC - PubMed
1. Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410. doi: 10.1182/blood-2015-08-665547. - DOI - PMC - PubMed
1. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2014;6:e2014073. doi: 10.4084/mjhid.2014.073. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 2016;14:357–362. doi: 10.1016/j.csbj.2016.09.003. - DOI - PMC - PubMed

[2] Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 2016;14:357–362. doi: 10.1016/j.csbj.2016.09.003. - DOI - PMC - PubMed

[3] Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer. 2016;63:1113–1115. doi: 10.1002/pbc.25953. - DOI - PubMed

[4] Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer. 2016;63:1113–1115. doi: 10.1002/pbc.25953. - DOI - PubMed

[5] Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295. doi: 10.1158/2159-8290.CD-15-1020. - DOI - PMC - PubMed

[6] Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295. doi: 10.1158/2159-8290.CD-15-1020. - DOI - PMC - PubMed

[7] Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410. doi: 10.1182/blood-2015-08-665547. - DOI - PMC - PubMed

[8] Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410. doi: 10.1182/blood-2015-08-665547. - DOI - PMC - PubMed

[9] Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2014;6:e2014073. doi: 10.4084/mjhid.2014.073. - DOI - PMC - PubMed

[10] Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2014;6:e2014073. doi: 10.4084/mjhid.2014.073. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

Affiliations

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

Authors

Affiliations

Conflict of interest statement

Competing interests

Publisher’s note

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources